Introduction
The HNK-1 monoclonal antibody (CD57, Leu-7) recognizes a sulfated carbohydrate determinant 1 expressed on glycoproteins of human peripheral blood lymphocytes 2 and various cell lines. 3 The exact role of CD57 is unknown, although there is evidence for its involvement in cell-cell and cell-substrate interactions during ontogeny 1 and leukocyte trafficking via Pand L-selectin. 4 Within the lymphocyte compartment, CD57 is found on a subset of natural killer (NK) cells, as well as on subsets of CD4 + and CD8 + T lymphocytes. 5 CD57 + T cells constitute a minor fraction of lymphocytes in healthy individuals. 6 Aberrant expansions of CD57 + T cells have been associated with a number of clinical disorders, including human immunodeficiency virus (HIV) or human cytomegalovirus infection, allotransplantation, rheumatoid arthritis, inflammatory bowel diseases, common variable immunodeficiency, congenital clotting disorders and Down's syndrome. 
CD57
+ lymphocytes from normal subjects inhibit pokeweed mitogen driven B cell differentiation, proliferation and immunoglobulin (Ig) production [8] [9] [10] in a contactdependent manner, 10 and they exhibit lectin-dependent and anti-CD3 redirected cytotoxic activity, 11 as well as antigenspecific cytotoxicity.
12 CD8 + CD57 + lymphocytes from bone marrow transplant and HIV-infected patients produce a 20-30 kDa concanavalin A-binding, soluble factor able to suppress lectin-driven proliferation and cell-mediated cytotoxicity. 13, 14 
CD4
+ CD57 + lymphocytes from normal subjects do not express mRNA for interleukin-2 (IL-2), IL-4 and CD40 ligand under conditions where CD4 +
CD57
− cells normally do so, 15 and CD4 + CD57 + lymphocytes from both normal subjects and cancer patients have a reduced capacity to support B cell activation/differentiation. 15, 16 Recently, it has been demonstrated that almost all CD57
+ T cells lack expression of the B7 counter-receptor CD28, 17 which is generally considered to be very important as a second signal receptor for T cell activation. 18 − T cells were shown to contain marked oligoclonal expansions, indicating that an antigen-specific recognition event is responsible for their induction and/or expansion. 20, 21 In the present study, we examined the frequency of CD57 +
/CD28
− T cells in peripheral blood of untreated hemato-oncological patients, and explored their functional capacities in vitro in cytotoxicity and cytokine secretion assays. Our analyses demonstrate that the proportions of CD57
− cells are increased among both CD4 + and CD8 + T cell subsets of hemato-oncological patients and differ significantly from their CD57 − /CD28 + counterparts with respect to cytokine secretion, cytolytic capacities, and susceptibility to apoptosis.
Materials and methods

Patients and controls
Peripheral blood was obtained from 55 healthy adult volunteers (aged 19 to 58 years; mean ± s.d. = 38.6 ± 10.4 years) and from 54 newly diagnosed, untreated patients with various hematological neoplasms (aged 19 to 91 years; mean ± s.d. = 58.2 ± 18.0 years; Table 1 ). Patients with lymphoma were classified according to the revised European-American classification of lymphoid neoplasms. 22 Patients with acute leukemia and MDS were classified in accordance with criteria from the French-American-British (FAB) group. 23 Patients with MM were staged according to the Durie-Salmon classification. 24 None of the patients or donors had experienced infections in the month preceding venepuncture. 
Monoclonal antibodies (mAb), cell lines and other reagents
Anti-CD3, anti-CD4, anti-CD8, anti-CD16, anti-CD25, anti-CD28, anti-CD54, anti-CD56, anti-CD57, anti-CD62L, anti-CD69, anti-CD71, anti-HLA-DR, and the appropriate mouse immunoglobulin isotype controls were from Becton Dickinson (Erembodegem, Belgium). Anti-Fas (anti-CD95) was from Immunotech (Marseille, France). Anti-MHC class I was from One Lambda (Canoga Park, CA, USA). mAb UCHT1 (anti-CD3, IgG1) used for polyclonal activation of T cells in cytokine assays, was a gift from Dr P Beverley (Imperial Research Cancer Fund, London, UK). Humanized anti-Tac (anti-CD25, specific for the ␣ chain of the IL-2 receptor) and humanized Mik␤1 (anti-CD122, specific for the IL-2 receptor ␤ chain) used for blocking IL-2 consumption in IL-2 production assays, were gifts from Dr J Hakimi at Hoffmann-La Roche (Nutley, NJ, USA). The hybridomas producing mAb OKT3 (anti-CD3, IgG2a) and HNK-1 (anti-CD57, IgM) used for anti-CD3-redirected cytotoxicity assays and immunomagnetic depletion of CD57 + lymphocytes, respectively, were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The P815 cell line, an NK-resistant DBA/2-derived murine mastocytoma cell line that expresses mouse Fc␥RII and Fc␥RIII, was obtained from the ATCC. Annexin V used 
Figure 1
Frequency of CD57 + and CD28 − cells among circulating CD4 + (a) and CD8 + (b) T lymphocytes of healthy controls (n = 55) and untreated hemato-oncological patients (n = 54). The mean within each subgroup is represented by a line. The patient group demonstrates a significantly higher proportion of CD57 + and CD28 − cells among both CD4
+ and CD8 + T lymphocytes (P Ͻ 0.0001).
for detection of apoptosis, was from Bender MedSystems (Vienna, Austria).
Leukocyte differential counts
Leukocyte differential counts were measured within 5 h after venepuncture on a Technicon H-2 automatic blood cell analyser (Miles, Tarrytown, NY, USA).
Immunofluorescence studies
Multicolor analyses were performed by direct immunofluorescence with FITC (fluorescein isothiocyanate)-, PE (phycoerythrin)-, and/or PerCP (peridinin chlorophyll protein)-conjugated mAb on a Facscan flow cytometer (Becton Dickinson). Optimization of the flow cytometer for three-color analysis was done in three steps: (1) unstained, FITC-, and PElabeled Calibrite beads (Becton Dickinson) and the Autocomp software program (Becton Dickinson) were used to optimize the cytometer for two-color analysis; (2) three tubes containing normal peripheral blood stained with anti-CD4-FITC, anti-CD8-PE and anti-CD3-PerCP, respectively, were used to further optimize the fluorescence (FL) FL2-%FL1 and FL1-%FL2 compensation levels, and to optimize settings of the FL3 detector and the FL3-%FL2 compensation level; and (3) a tube containing normal peripheral blood stained with anti-CD4-FITC/anti-CD8-PE/anti-CD3-PerCP was used to verify that the fluorescence compensation levels were correct. Staining and analysis of the lymphocytes was performed as follows: 100 l cell suspension (isolated cells or peripheral blood, eventually diluted with phosphate-buffered saline to a maximum of 10 × 10 6 cells/ml) was incubated with the directly conjugated mAb. After 15 min, the cells were either washed (isolated cells), or incubated with Facs lysing solution (Becton Dickinson) for 10 min to lyse the erythrocytes (peripheral blood). The cells were then centrifuged and fixed in 0.5 ml of a 0.5% paraformaldehyde/PBS solution, and analyzed on the flow cytometer. Annexin V binding of the cells for detection of apoptosis 25 was determined by incubating the cells for 5 min with annexin V-FITC, and direct FACS analysis. Data obtained by flow cytometry were analyzed by gating on the lymphocytes using forward (FSC) and side light scatter (SSC) in the Lysis II software program (Becton Dickinson). The FSC/SSC analysis gate was set to include at least 95% of the nonmalignant lymphocytes, which were discriminated from contaminating erythrocytes, monocytes and tumor cells on the basis of light scatter signals and fluorescence profiles of CD14/CD45 markers (two-color immunofluorescence), CD14/CD(13+33)/ CD45 markers (three-color immunofluorescence) and/or specific marker combinations identifying the tumor cells (for example, anti-kappa/anti-lambda/anti-CD19 and/or antiCD11c/anti-CD19 for B-CLL and hairy cell leukemia; anti-CD10/anti-CD19 and anti-kappa/anti-lambda/anti-CD19 for B-ALL). The nonmalignant CD4
+ and CD8 + T cells were immunophenotypically identified as CD3 high CD4
high and CD3 high CD4 − lymphocytes, respectively, which were simultaneously analyzed for expression of other cell surface markers in the third color. Nonmalignant CD4 + T cells were discriminated from blast cells with aberrant CD4 expression by (1) a lower expression (fluorescence intensity) of CD4 on the blast cells; (2) absence or only dim expression of CD3 on the blast cells; and/or (3) an additional tumor-associated marker not expressed by CD4
+ T cells (anti-CD33 and/or anti-CD34 in myeloid leukemias, for example). Ten thousand cells were routinely analyzed for each marker combination.
Cell separation
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation over a Lymphoprep (density 1.077) gradient (Nycomed, Oslo, Norway). After three washings in Hank's balanced salt solution (HBSS; Gibco, Paisley, UK) containing 1% heat-inactivated iron-supplemented bovine calf serum (BCS; Hyclone, Logan, UT, USA), the cells were resuspended in RPMI 1640 (Gibco), supplemented with 2 mM Lglutamine (Gibco), penicillin (100 U/ml, Gibco), streptomycin (100 g/ml, Gibco), and 10% iron-supplemented bovine calf Association of CD57 with CD28 expression on circulating T lymphocytes of untreated hemato-oncological patients. CD4 + and CD8
+ T cells were purified with Dynabeads (Ͼ95% pure) from peripheral blood of a patient with B-CLL and of a patient with mantle cell lymphoma, respectively, and were stained with anti-CD57-FITC, anti-CD28-PE, and anti-CD4-PerCP (or anti-CD8-PerCP) and analyzed on a FACS. FACS fluorescence dot plots (a, d) show the expression levels (fluorescence intensities, on a 4-log scale) of CD4/CD57 (a) and CD8/CD57 cell surface antigens (d). The CD57 + and CD57 − cells were gated and analyzed for expression of CD28 in the third color. FACS histograms (b-c, e-f) show the relative cell number vs the fluorescence intensity (on a 4-log scale). The dotted line shows the staining with control mouse IgG.
serum (BCS) (complete medium). For purification of CD3
+ CD4 + and CD3 + CD8 + lymphocytes, magnetic immunoselection on PBMC with anti-CD4-and anti-CD8-coated Dynabeads (Dynal, Oslo, Norway) respectively, was used. The beads were applied with a bead-to-target ratio of 3:1, and the selected cells were detached from the beads using Detachabead solution (Dynal), resulting in over 95% pure
cells. For purification of CD57
+
/CD28
− and CD28 + /CD57 − T cells, rat anti-mousecoated Dynabeads (Dynal) were incubated overnight with an excess of anti-CD28 or anti-CD57 mAb, and used in a negative selection procedure. The beads were applied with a bead- 
Cytokine production and detection
For the production of cytokines, 0.25 × 10 6 immunomagnetically purified CD4
+ CD57 − , and CD8
− peripheral blood T lymphocytes were cultured in 1 ml complete medium in 24-well flat-bottomed tissue culture plates coated with UCHT1 mAb. This anti-CD3 mAb was shown to have a strong stimulatory capacity in the absence of accessory signals. 26 Culture plates were coated by incubating the wells with UCHT1 (5 g/ml) in 300 l PBS for 4 h at 37°C, and then washed three times for 3 min with PBS. For IL-2 production, anti-Tac (anti-CD25) and anti-Mik␤1 (anti-CD122) mAb (both at 1 g/ml) were added from the beginning of the culture period to reduce IL-2 consumption.
27 After 23-58 h of stimulation, the supernatants were collected for cytokine detection. Tumor necrosis factor-␣ (TNF-␣) concentration in supernatants was determined with the Innotest hTNF-alpha kit (Innogenetics, Gent, Belgium). IL-2, IL-4, IL-5, IL-10 and interferon-␥ (IFN-␥) concentrations were determined with a sandwich ELISA technique, using combinations of unlabelled and biotin-coupled mAb to different epitopes of each cytokine as described 28 (anti-IL-2 mAb was obtained from Genzyme, Cambridge, MA, USA; anti-IL-4, anti-IL-5, and anti-IFN-␥ mAb were obtained from Medgenix Diagnostics, Fleurus, Belgium; anti-IL-10 mAb was obtained from Pharmingen, San Diego, CA, USA).
Cytotoxicity assays
Ex vivo cytotoxic activity was measured in a 4-h target cell lysis assay using murine P815 mastocytoma cells as (NK resistant) targets and OKT3 (2 g/ml) as anti-CD3 bridging mAb, as previously described. 29 This redirected cytotoxicity assay evaluates all T cell cytotoxic activity, irrespective of antigen specificity. 30 Lysis of P815 cells in the absence of bridging mAb was used to detect 'lymphokine-activated killer (LAK)-like' activity of cytotoxic T cells.
Statistical analysis
The statistical significance of differences between the various groups was determined by the nonparametric Wilcoxon ranking test. P values Ͻ0.05 were regarded as significant. Linear regression analysis was performed to evaluate the influence of age. 
Results
CD57
+
cells are increased in untreated hemato-oncological patients
We first studied the expression of CD57 and CD28 on CD4 + and CD8 + T cells in peripheral blood of 55 healthy donors and 54 untreated hemato-oncological patients by three-color immunofluorescence on whole blood samples. Anti-CD3 and anti-CD4 mAb were used to delineate the CD3 +
CD4
+ and CD3
T cell subsets, which were simultaneously analyzed for expression of CD57 or CD28 in the third color. The majority of CD3 + CD4 − T cells from both patients and donors expressed CD8 (91% ± 6% and 92% ± 5%, respectively), so we will further label these cells as CD8 + T cells. As shown in Figure 1 (a and b) , the patient group demonstrated a markedly higher proportion of CD57 + and CD28 − cells among both CD4 + and CD8 + T cells. The frequency of CD57 + cells within the CD4 + subset was 3.4% ± 3.9% for controls, compared with 11.2% ± 11.9% for the patients (P Ͻ 0.0001); within the CD8 + T cell subset the frequency of CD57 + cells was 26.3% ± 12.3% for controls, compared with 42.9% ± 18.6% for the patients (P Ͻ 0.0001). The frequency of CD28 − cells within the CD4 + subset was 1.4% ± 2.8% for controls, compared with 7.3% ± 10.4% for the patients (P Ͻ 0.0001); within the CD8 + T cell subset the frequency of CD28 − cells was 25.0% ± 13.2% for controls, compared with 42.4% ± 18.0% for the patients (P Ͻ 0.0001).
The patients' CD57 + and CD28 − T cells were significantly increased not only in relative contribution to the whole Table 3 Cytokine production (pg/ml) by freshly isolated CD57 (nonmalignant) lymphocyte population but also in absolute numbers (Table 2) . Additional three-color immunofluorescence analysis revealed that CD57 and CD28 expression on the patients' T cells is largely reciprocal (Figure 2 ; note, however, that in some patients a relatively large proportion of CD28 − cells could be detected among CD8 + CD57 − T lymphocytes: f in Figure 2 , for instance). This observation suggested the use of anti-CD57-and anti-CD28-coated Dynabeads for purification of reciprocal CD57 +
/CD28
− and CD57 − /CD28 + T cell subsets for functional analysis.
Analysis of age variation in the distribution of CD57
+ /CD28 − T cells
Recently, CD8 + CD57 + /CD28 − T cells have been reported to increase progressively with age. 19 As the patient group was significantly older than the control group (58.2 ± 18.0 years and 38.6 ± 10.4 years, respectively, P Ͻ 0.0001), a linear regression analysis was performed to evaluate the influence of age on CD57
− T cell subset numbers. As shown in Figure 3 , the patient group demonstrated a significant increase with age of the CD57
− cells among circulating CD8 
Figure 5
Correlation between ex vivo cytotoxic activity of purified CD8 + (a, b) and CD4 + (c, d) peripheral blood T cell subsets of untreated hemato-oncological patients and the proportion of CD57 + (a, c) and CD28 − (b, d) cells within these subsets. CD8 + T cells were purified with Dynabeads (Ͼ95% pure) from peripheral blood of 28 patients (two mantle cell lymphomas, two lymphoplasmacytoid lymphomas, two diffuse large B cell lymphomas, one Hodgkin's disease, one AML M3, one T-ALL L2, one B-ALL L2, two CML, eight B-CLL, two HCL, two MM, three MDS RAEBt, and one secondary MDS); CD4 + T cells were purified with Dynabeads (Ͼ95% pure) from the peripheral blood of six B-CLL patients. CD57 and CD28 expression were determined by direct three-color immunofluorescence FACS analysis. Murine P815 cells and anti-CD3 mAb were used to detect cytotoxic activity regardless of antigen specificity.
for CD57
+ cells and +0.3%/decade for CD28 − cells), which was not, however, statistically significant (P Ͼ 0.05). Since a significant age-associated increase of CD57
− cells was detected among the CD8 + T lymphocytes, an age correction [(38.6 − age) × slope of the age trend (ie 0.43 for the CD57 + cells, 0.37 for the CD28 − cells)] was done to normalize the data of the older patients to that of the control population.
Comparison of the age-adjusted patient data with that of the healthy controls revealed that the proportion of CD57 + and CD28 − cells among circulating CD8 + T lymphocytes was still significantly higher in the patient group (34.5% ± 16.7% and 35.2% ± 16.0%, respectively) as compared to the controls (26.3% ± 12.3% CD57 + cells, P = 0.0103; 25.0% ± 13.2% CD28 − cells, P = 0.0026). The age-adjusted absolute numbers of circulating CD8 +
CD57
+ and CD8 + CD28 − T cells in patients (mean ± s.e. = 360 ± 67 cells/l and 308 ± 47 cells/l, respectively) also remained significantly higher than in healthy controls (164 ± 21 CD8 + CD57 + cells/l, P = 0.0160; 160 ± 22 cells/l CD8 +
CD28
− T cells, P = 0.0069).
Marked expansion of CD57 + cells among circulating CD4 + T lymphocytes is common in B-CLL and HCL patients but not in CML patients
Marked expansion of CD57
+ cells among circulating CD4 + T lymphocytes was frequently detected in patients with chronic leukemia of B cell origin (B-CLL, HCL), while patients with CML displayed near normal levels of these cells (Figure 4a ). The frequency of CD57 + cells among circulating CD4 + T lymphocytes was 22.2% ± 14.8% for the group of B-CLL and HCL patients, compared with 5.8% ± 3.6% for the CML patients (P = 0.0070). Within the CD8 + T lymphocytes on the other hand, the frequency of CD57 + cells was equally high in both patient groups (51.0% ± 16.9% for the group of B-CLL and HCL patients, and 47.6% ± 20.5% for the CML patients) ( Figure  4b ). As B-CLL and HCL patients contain massive amounts of circulating tumor cells which strongly express both MHC class I and class II molecules (not shown), while CML patients harbor massive amounts of circulating tumor cells which strongly express MHC class I molecules only (not shown), this suggests that the enhanced expression of CD57 within the patients' circulating CD4 + and (or) CD8 + T cells is related to the tumor's MHC class II and (or) class I expression, respectively.
CD57 + /CD28 − peripheral blood T cells of untreated hemato-oncological patients display Th1-type cytokine secretion upon stimulation with anti-CD3
To examine the function of the expanded CD57 + /CD28 − T cells in untreated hemato-oncological patients, we first com- 
/CD28
+ counterparts. To this end, the reciprocal T cell subsets were immunomagnetically purified from peripheral blood CD4 + and CD8 + T lymphocyte samples containing high proportions of CD57
The freshly purified T cell subsets were stimulated with plate-fixed anti-CD3, and the cytokine concentrations in the supernatants were determined by ELISA. As shown in Table 3 , anti-CD3-triggered CD57
− T cells produced significantly higher amounts of the Th1-type cytokines IL-2, TNF-␣, and IFN-␥ than their CD57 − /CD28 + counterparts. None of the anti-CD3-triggered subsets produced significant levels of the Th2-type cytokines IL-4, IL-5 and IL-10 (data not shown). None of the cytokines was detected in the supernatants of the unstimulated subsets.
The CD57
+ /CD28 − subset contains the circulating active cytolytic CD4
+ and CD8 + T cells in untreated hemato-oncological patients Next, we investigated the cytolytic capacities of CD57
− T cells. Fc␥R-expressing mouse mastocytoma P815 cells and anti-CD3 mAb were used to detect ex vivo cytotoxic T lymphocyte (CTL) activity regardless of antigenspecificity of the cytotoxic effector cells. As shown in Figure  5 for cytolytic experiments performed at 20:1 effector:target ratio, ex vivo cytotoxic activity within the patients' CD8 + (n = 28) and CD4 + T cell subsets (n = 6) significantly correlated with the proportion of CD57 + and CD28 − cells within these subsets. Similar correlations were observed at 2.5:1, 5:1, and 10:1 effector:target ratios (data not shown). With the exception of CD56 expression on CD4 + T cells (r = +0.95, P = 0.0040), no significant correlation was found between cytotoxic activity of the patients' T cells and their expression of other activation markers (CD69, CD25, CD45RA, CD54, HLA-DR, CD71, CD56 and CD62L; data not shown). Relevant to the former observation, additional three-color stainings revealed that CD56 expression on CD4 + T cells of the six B-CLL patients was largely restricted to the CD57 + subset (not shown). Cytotoxic activity within the CD8 + T cells of five healthy donors was also significantly correlated with the CD28 − subset at all effector:target ratios (r = ෂ+0.90, P Ͻ 0.05). As shown in Figure 6 (a and b) , depletion of the CD57 + and CD28 + cells from either the CD8 + or CD4 + T cell subsets resulted in a significant reduction and enhancement, respectively, of their ex vivo cytotoxic activity. These experiments confirm that cytolytic effectors are mainly contained within the CD57
cells of untreated hemato-oncological patients display an increased tendency to apoptosis
We observed that anti-CD3-triggered CD57
− T cells after 58 h of culture displayed higher proportions of cells with typical features of apoptosis (reduced forward scatter, increased side scatter, and increased annexin V binding 
/CD28
+ counterparts (Figure 7) . Addition of IL-2 (10 U/ml) to the cultures did not appear to have a protective effect on either subset (not shown). Fas (CD95), known as receptor for the induction of apoptosis, was similarly expressed on the cell surface of CD28 − (CD57 + ) and CD28
+ peripheral blood T cells of three patients tested (mean fluorescence intensity 51 ± 11 and 66 ± 15, respectively).
Discussion
In the present study, we show that CD57
− T cells are expanded in the peripheral blood of untreated hemato-oncological patients, and that these cells display (1) a Th1-type cytokine secretion profile; (2) ex vivo polyclonal cytotoxic activity; and (3) an increased tendency to apoptosis. The expansion of CD57
− T cells in hemato-oncological patients cannot simply be explained by the difference in age between patients (58.2 ± 18.0 years) and healthy controls (38.6 ± 10.4 years), since adjustment for age of the patient data to that of the control population revealed that both the relative and absolute numbers of CD57 + /CD28 − T cells remained significantly higher in the patient population.
Analysis of the cytokine secretion capacities of CD57
− T cells revealed a predominant Th1-type cytokine secretion profile, with a markedly higher secretion of the Th1-type cytokines IL-2, IFN-␥ and TNF-␣ than their CD57 −
/CD28
+ counterparts when stimulated with anti-CD3 alone. Similar findings have been reported for CD57 + T cells of healthy donors. 31 In contrast to their CD57 − /CD28 + counterparts, the patients' CD57 + /CD28 − T cells also displayed significant ex vivo cytotoxic activity. Cytolytic effector potential of CD8
− T cells is well documented, 11, 32 but to our knowledge this is the first time that ex vivo cytotoxic activity has been demonstrated within peripheral CD4
− T cells. Despite the expansion of the CD28 − subset among CD8 + T cells of hemato-oncological patients and the significant correlation of cytotoxicity with the CD28 − subset in CD8 + T cells of both patients and donors, CD8 + T cells of patients and donors display similar cytotoxic activities. 33 This suggests that the expanded CD8 + CD28 − / CD57 + T cell subset in hemato-oncological patients either has a lower cytolytic potential on a per cell basis than in healthy controls, or that it rapidly progresses to apoptosis upon triggering (see below), or that it contains an important fraction of cells with other than cytotoxic functions. Relevant to the latter possibility, regulatory or suppressive functions by CD8
− T cells have been described by several groups. [8] [9] [10] [34] [35] [36] In HIV-infected subjects CD8 
CD57
+ T cells and their oligoclonality correlates with disease stage, suggesting a potential role of these cells in the pathophysiology of CLL. Furthermore, as dramatic oligoclonal expansions were also shown to be a characteristic feature of CD8 +
+ T cells, 21 the expanded CD57 + T cells in hemato-oncological patients presumably correspond to oligoclonal T cell expansions, possibly elicited by tumor antigens presented in the context of MHC molecules. However, in preliminary experiments we were unable to demonstrate tumor-directed cytotoxic activity of CD4 + (n = 3, all from B-CLL patients) and CD8 + T cell samples (n = 8, from one diffuse large B cell lymphoma, one CML, five B-CLL, and one HCL) containing high proportions of CD57 + (CD28 
CD28
− T cell clones cytolytic to the autologous tumor cells but not to the autologous bone marrow remission cells of three children with acute leukemia. However, these clones also lysed allogeneic blasts in a MHCunrestricted manner, and also exerted strong cytolytic activity against K562 targets, suggesting LAK rather than (tumorspecific) CTL effector function. Another possibility is that the CD4
− T cell expansions in hemato-oncological patients may be related to autoimmune phenomena. First, expansions of peripheral CD4 +
− T cells in healthy donors significantly correlate with specific MHC class II alleles associated with some autoimmune diseases. 41 Peripheral CD4 +
− T cells and/or T cell clones from patients with rheumatoid arthritis and type I diabetes are autoreactive, ie they respond to autologous antigen-presenting cells in the 
CD57
+ T cells prevail in higher percentages in B-CLL patients with advanced disease stages than in patients with early stages. 39, 43 Finally, autoimmune disorders are being recognized with increasing frequency in patients with HCL, 44 and have also been associated with NHL 45 but not with CML. 46 In conclusion, our results indicate that the expanded CD57
− T cells in hemato-oncological patients represent differentiated effector cells, similar to their (quantitatively minor) counterpart in healthy donors. Further studies are required to define the induction, specificity and basic biology of these cells. These studies should provide more information on their possible (pathophysiologic) role in vivo.
